$NUGN
Livento Group Inc Stock $nugn

$nugn Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000149315223016857 Filed on May 15, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022 Q1
Revenue	$491.5K		$455.2K
YoY Change	7.96%
Cost Of Revenue	$931.6K		$424.8K
YoY Change	119.32%
Gross Profit	-$440.2K		$30.44K
YoY Change	-1546.12%
Gross Profit Margin	-89.56%		6.69%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$5.032M
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$375.4K		$28.20K
YoY Change	1231.55%
Operating Profit	-$815.6K		$2.243K
YoY Change	-36462.15%
Interest Expense	$0.00		$0.00
YoY Change
% of Operating Profit			0.0%
Other Income/Expense, Net	-$11.00		$0.00
YoY Change
Pretax Income
YoY Change
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$815.6K		$2.243K
YoY Change	-36462.59%
Net Earnings / Revenue	-165.95%		0.49%
Basic Earnings Per Share	$0.00		$0.00
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding	248.0M shares	227.0M shares	227.0M shares
Diluted Shares Outstanding	248.0M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$96.49K	$24.16K	$100.7K
Short-Term Investments
Other Short-Term Assets	$107.1K	$121.5K
YoY Change
Inventory	$0.00	$0.00
Prepaid Expenses
Receivables	$478.0K	$489.9K
Other Receivables
Total Short-Term Assets	$681.6K	$635.5K
YoY Change		31.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$0.00
YoY Change
Goodwill	$0.00	$0.00
YoY Change
Intangibles	$15.37M	$12.73M
YoY Change		58.43%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$22.52M	$22.68M
YoY Change		13.61%
TOTAL ASSETS
Total Short-Term Assets	$681.6K	$635.5K
Total Long-Term Assets	$22.52M	$22.68M
Total Assets	$23.20M	$23.32M
YoY Change		14.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$295.7K	$139.5K
YoY Change		-46.11%
Accrued Expenses	$100.00	$62.55K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.362M	$3.248M
YoY Change		1154.58%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.362M	$3.248M
Total Long-Term Liabilities
Total Liabilities	$3.362M	$3.248M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$13.27M	-$12.45M
YoY Change		4.07%
Common Stock	$24.80K	$22.70K
YoY Change		-70.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$19.84M	$20.07M	$20.19M
YoY Change
Total Liabilities & Shareholders Equity	$23.20M	$23.32M
YoY Change		14.03%

Cashflow Statement

Concept	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$815.6K	$2.243K
YoY Change	-36462.59%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$276.3K	-$167.2K
YoY Change	65.18%
INVESTING ACTIVITIES
Capital Expenditures	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$255.4K	-$216.3K
YoY Change	18.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$2.100K	-$56.64K
YoY Change	-103.71%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$603.9K	$0.00
YoY Change
NET CHANGE
Cash From Operating Activities	-$276.3K	-$167.2K
Cash From Investing Activities	-$255.4K	-$216.3K
Cash From Financing Activities	$603.9K	$0.00
Net Change In Cash	$72.33K	-$383.5K
YoY Change	-118.86%
FREE CASH FLOW
Cash From Operating Activities	-$276.3K	-$167.2K
Capital Expenditures	$0.00
Free Cash Flow	-$276.3K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001593549
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-56457
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Livento Group, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3999052
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	17 State Street
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 4000
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10004
CY2023Q1	dei	City Area Code CityAreaCode	980
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	432-8241
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	248001268	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96486	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24159	usd
CY2023Q1	NUGN	Total Checking Savings TotalCheckingSavings	96486	usd
CY2022Q4	NUGN	Total Checking Savings TotalCheckingSavings	24159	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	478000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	489910	usd
CY2023Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	107099	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	121460	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	0	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	107099	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	121460	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	681585	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	635529	usd
CY2023Q1	us-gaap	Long Term Investments LongTermInvestments	9958241	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	9952880	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2023Q1	us-gaap	Goodwill Goodwill	0	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023Q1	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	15368847	usd
CY2022Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	15118847	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	0	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	0	usd
CY2023Q1	NUGN	Deferred Long Term Asset Charges DeferredLongTermAssetCharges	0	usd
CY2022Q4	NUGN	Deferred Long Term Asset Charges DeferredLongTermAssetCharges	0	usd
CY2023Q1	NUGN	Accumulated Depreciation AccumulatedDepreciation	-2811352	usd
CY2022Q4	NUGN	Accumulated Depreciation AccumulatedDepreciation	-2391999	usd
CY2023Q1	NUGN	Total Fixed Assets TotalFixedAssets	22515735	usd
CY2022Q4	NUGN	Total Fixed Assets TotalFixedAssets	22679728	usd
CY2023Q1	us-gaap	Assets Assets	23197321	usd
CY2022Q4	us-gaap	Assets Assets	23315257	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	295717	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	139530	usd
CY2023Q1	NUGN	Credit Cards CreditCards	0	usd
CY2022Q4	NUGN	Credit Cards CreditCards	0	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	100	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	62549	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2023Q1	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	0	usd
CY2022Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	0	usd
CY2023Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	0	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	0	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	100	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	62549	usd
CY2023Q1	NUGN	Co Investments CoInvestments	3066017	usd
CY2022Q4	NUGN	Co Investments CoInvestments	3046017	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3361834	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3248096	usd
CY2023Q1	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	0	usd
CY2022Q4	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	0	usd
CY2023Q1	us-gaap	Liabilities Liabilities	3361834	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3248096	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	33071956	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	32493023	usd
CY2023Q1	NUGN	Capital Stock CapitalStock	0	usd
CY2022Q4	NUGN	Capital Stock CapitalStock	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	248001268	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	227001268	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	24800	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	22700	usd
CY2023Q1	NUGN	Dividends Paid DividendsPaid	0	usd
CY2022Q4	NUGN	Dividends Paid DividendsPaid	0	usd
CY2023Q1	NUGN	Opening Balance Equity OpeningBalanceEquity	0	usd
CY2022Q4	NUGN	Opening Balance Equity OpeningBalanceEquity	0	usd
CY2023Q1	us-gaap	Members Capital MembersCapital	0	usd
CY2022Q4	us-gaap	Members Capital MembersCapital	0	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13266410	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12450797	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	19835487	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	20067160	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23197321	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23315257	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	491468	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	455217	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	931639	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	424779	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	-440171	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	30438	usd
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	13093	usd
CY2022Q1	us-gaap	Advertising Expense AdvertisingExpense	22534	usd
CY2023Q1	us-gaap	Payments For Software PaymentsForSoftware	0	usd
CY2022Q1	us-gaap	Payments For Software PaymentsForSoftware	0	usd
CY2023Q1	NUGN	Bank Service Charges BankServiceCharges	553	usd
CY2022Q1	NUGN	Bank Service Charges BankServiceCharges	124	usd
CY2023Q1	us-gaap	Insurance Commissions InsuranceCommissions	54010	usd
CY2022Q1	us-gaap	Insurance Commissions InsuranceCommissions	0	usd
CY2023Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	143565	usd
CY2022Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	966	usd
CY2023Q1	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	0	usd
CY2022Q1	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	0	usd
CY2023Q1	us-gaap	Other General Expense OtherGeneralExpense	3112	usd
CY2022Q1	us-gaap	Other General Expense OtherGeneralExpense	3848	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	0	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	0	usd
CY2023Q1	us-gaap	General Insurance Expense GeneralInsuranceExpense	1020	usd
CY2022Q1	us-gaap	General Insurance Expense GeneralInsuranceExpense	0	usd
CY2023Q1	us-gaap	Legal Fees LegalFees	17618	usd
CY2022Q1	us-gaap	Legal Fees LegalFees	0	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	77700	usd
CY2022Q1	us-gaap	Professional Fees ProfessionalFees	500	usd
CY2023Q1	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	1147	usd
CY2022Q1	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	40	usd
CY2023Q1	us-gaap	Other Labor Related Expenses OtherLaborRelatedExpenses	51904	usd
CY2022Q1	us-gaap	Other Labor Related Expenses OtherLaborRelatedExpenses	0	usd
CY2023Q1	NUGN	Rental Expense RentalExpense	2614	usd
CY2022Q1	NUGN	Rental Expense RentalExpense	183	usd
CY2023Q1	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	9096	usd
CY2022Q1	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	0	usd
CY2023Q1	us-gaap	Other Expenses OtherExpenses	0	usd
CY2022Q1	us-gaap	Other Expenses OtherExpenses	0	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	375431	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	28195	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-815603	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	2243	usd
CY2023Q1	us-gaap	Other Income OtherIncome	0	usd
CY2022Q1	us-gaap	Other Income OtherIncome	0	usd
CY2023Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	11	usd
CY2022Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-815613	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	2243	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	248001268	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	227001268	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-815613	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	2243	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-815613	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2243	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	20067160	usd
CY2023Q1	NUGN	Stock Issued During Period Value Change In Preferred Shares StockIssuedDuringPeriodValueChangeInPreferredShares	2997	usd
CY2023Q1	NUGN	Stock Issued During Period Value Change In Ordinary Shares StockIssuedDuringPeriodValueChangeInOrdinaryShares	2100	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	578843	usd
CY2023Q1	NUGN	Stock Issued During Period Value Change In Accumulated Deficit StockIssuedDuringPeriodValueChangeInAccumulatedDeficit	-815613	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	19835487	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	20187883	usd
CY2022Q1	NUGN	Stock Issued During Period Value Change In Preferred Shares StockIssuedDuringPeriodValueChangeInPreferredShares	620	usd
CY2022Q1	NUGN	Stock Issued During Period Value Change In Ordinary Shares StockIssuedDuringPeriodValueChangeInOrdinaryShares	-56638	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	56017	usd
CY2022Q1	NUGN	Stock Issued During Period Value Change In Accumulated Deficit StockIssuedDuringPeriodValueChangeInAccumulatedDeficit	2243	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	20190126	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-815613	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	2243	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-11910	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	445000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-0	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-0	usd
CY2023Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	419353	usd
CY2022Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	419353	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	108098	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-143837	usd
CY2023Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	usd
CY2022Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	0	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	0	usd
CY2023Q1	NUGN	Payroll Liabilities PayrollLiabilities	0	usd
CY2022Q1	NUGN	Payroll Liabilities PayrollLiabilities	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	0	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	0	usd
CY2023Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	539361	usd
CY2022Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-169488	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-276253	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-167241	usd
CY2023Q1	us-gaap	Payments For Proceeds From Longterm Investments PaymentsForProceedsFromLongtermInvestments	255360	usd
CY2022Q1	us-gaap	Payments For Proceeds From Longterm Investments PaymentsForProceedsFromLongtermInvestments	216273	usd
CY2023Q1	NUGN	Furniture And Equipment FurnitureAndEquipment	-0	usd
CY2022Q1	NUGN	Furniture And Equipment FurnitureAndEquipment	-0	usd
CY2023Q1	NUGN	Deposits Investing Activities DepositsInvestingActivities	-0	usd
CY2022Q1	NUGN	Deposits Investing Activities DepositsInvestingActivities	-0	usd
CY2023Q1	NUGN	Proceeds From Security Deposits Asset ProceedsFromSecurityDepositsAsset	0	usd
CY2022Q1	NUGN	Proceeds From Security Deposits Asset ProceedsFromSecurityDepositsAsset	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-255360	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-216273	usd
CY2023Q1	NUGN	Proceeds From Issuance Of Additional Paidin Capital ProceedsFromIssuanceOfAdditionalPaidinCapital	578843	usd
CY2022Q1	NUGN	Proceeds From Issuance Of Additional Paidin Capital ProceedsFromIssuanceOfAdditionalPaidinCapital	56017	usd
CY2023Q1	NUGN	Proceeds From Issuance Of Capital Stock ProceedsFromIssuanceOfCapitalStock	0	usd
CY2022Q1	NUGN	Proceeds From Issuance Of Capital Stock ProceedsFromIssuanceOfCapitalStock	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2100	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-56638	usd
CY2023Q1	NUGN	Proceeds From Issuance Of Dividends Paid ProceedsFromIssuanceOfDividendsPaid	0	usd
CY2022Q1	NUGN	Proceeds From Issuance Of Dividends Paid ProceedsFromIssuanceOfDividendsPaid	0	usd
CY2023Q1	NUGN	Proceeds From Issuance Of Owner Or Member Capital ProceedsFromIssuanceOfOwnerOrMemberCapital	0	usd
CY2022Q1	NUGN	Proceeds From Issuance Of Owner Or Member Capital ProceedsFromIssuanceOfOwnerOrMemberCapital	0	usd
CY2023Q1	NUGN	Proceeds From Issuance Of Preferred Stock ProceedsFromIssuanceOfPreferredStock	2997	usd
CY2022Q1	NUGN	Proceeds From Issuance Of Preferred Stock ProceedsFromIssuanceOfPreferredStock	620	usd
CY2023Q1	NUGN	Proceeds From Co Investments ProceedsFromCoInvestments	20000	usd
CY2022Q1	NUGN	Proceeds From Co Investments ProceedsFromCoInvestments	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	603940	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	72327	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-383514	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24159	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	484183	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	96486	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	100669	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80C_eus-gaap--NatureOfOperations_zKVKH1QQFgmd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_823_zi5AiNh4RzB7">NATURE OF BUSINESS AND BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We were incorporated in the State of Nevada on October 30, 2013, under the name “Bling Marketing, Inc.”. Until December 29, 2014, we were a wholesaler of jewelry, principally earrings, rings, and pendants (“BMI Business”). We recognized a minimal number of sales from operations before the three months ending June 30, 2014 and were accordingly classified as a shell company. During the three-month ended June 30, 2014, we began working with several distributors to sell our jewelry products to retail outlets and, as a result, recognized sales revenue of $<span id="xdx_900_eus-gaap--ExciseAndSalesTaxes_c20140401__20140630__dei--LegalEntityAxis__custom--BlingMarketingIncMember_zn6iqocZFCqa" title="Sales revenue">22,025</span> during the said period. On September 11, 2014, we filed a Current Report on Form 8-K indicating that we were no longer a shell company as defined by Rule12b-2 of the Exchange Act in light of our operations through the quarter that ended June 30, 2014.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 26, 2014, we entered into an Agreement and Plan of Merger (“Nugene Merger Agreement”) with NuGene Inc., a California corporation (“NuGene”). On December 29, 2014 (the “Closing Date”), we filed a certificate of merger in the State of California whereby our subsidiary, NG Acquisition Inc. (“Acquisition Sub”), merged with NuGene. As a result, NuGene, the surviving entity, became our wholly owned subsidiary. The transaction under the Nugene Merger Agreement was deemed to be a reverse merger, whereby the Company (the legal acquirer) is considered the accounting acquiree and NuGene is considered the accounting acquirer, and NuGene (the legal acquiree) is considered the accounting acquirer. The assets, liabilities, and operations of the acquired entity, NuGene, were brought forward at their book value, and no goodwill was recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the NuGene Merger Agreement, we entered into a Business Transfer and Indemnity Agreement dated December 29, 2014 (the “Indemnity Agreement”) with our former Chief Executive Officer and Director, Dena Kurland providing for:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The transfer of our jewelry business operations existing on the date of the Indemnity Agreement (the “BMI Business”);</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assumption by Ms. Kurland of all liabilities of our Company and the indemnification by Ms. Kurland holding our Company harmless for any and all liabilities arising at or before the date of the Indemnity Agreement;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The payment by NuGene to Ms. Kurland of $<span id="xdx_901_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_c20141226__20141226__dei--LegalEntityAxis__custom--NuGeneIncMember__srt--TitleOfIndividualAxis__custom--MsKurlandMember_zjczah9geEqj" title="Payments to acquire business net of cash acquired">350,000</span> in cash; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The surrender by Ms. Kurland of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20141226__20141226__srt--TitleOfIndividualAxis__custom--MsKurlandMember_zr7i00ex6FP" title="Shares forfeited">15,000,000</span> shares (before giving effect to the Stock Split discussed below) (the “Indemnity Shares”) of our Company’s common stock representing <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_c20141226__20141226__dei--LegalEntityAxis__custom--NuGeneIncMember__srt--TitleOfIndividualAxis__custom--MsKurlandMember_z2AUkxbavNf3" title="Common stock, percentage">95</span>% of the then outstanding common stock (all of which shares have been deemed cancelled by the Company).</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Nugene Merger Agreement, <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20141226__20141226__dei--LegalEntityAxis__custom--NuGeneIncMember__us-gaap--TypeOfArrangementAxis__custom--NugeneMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z27CP0uzY5Ih" title="Stock issued during period shares new issues">26,052,760</span> shares of Company common stock and <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20141226__20141226__dei--LegalEntityAxis__custom--NuGeneIncMember__us-gaap--TypeOfArrangementAxis__custom--NugeneMergerAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zeaaOSXNmnfj" title="Stock issued during period shares new issues">1,917,720</span> Company a newly designated Series A Preferred Stock were issued to the former NuGene shareholders. The Series A Preferred Stock was: (i) initially convertible into common stock at a ratio of one to one, (ii) as long as there were a minimum of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20141226__20141226__dei--LegalEntityAxis__custom--NuGeneIncMember__us-gaap--TypeOfArrangementAxis__custom--NugeneMergerAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zBSdCvjyKASj" title="Stock issued during period shares new issues">900,000</span> shares of Series A Preferred Stock outstanding, the holders of the Series A Preferred Stock had the right to elect a majority of the board of directors and (iii) the holders of the Series A Preferred Stock, generally voting as a class with the holders of common stock, had for each share of Series A Preferred Stock three times the number of votes permitted to each share of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 26, 2014, our <span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20141226__20141226__srt--TitleOfIndividualAxis__srt--DirectorMember_ziVS04gmMLN5" title="Stockholders equity reverse stock split">board of directors approved a 15.04 to one stock split (“Stock Split”) in the form of a stock dividend to holders of our common stock as of that date. To affect that board action, each recipient of the stock dividend would receive 14.04 additional shares of common stock</span> for every share of common stock held.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 29, 2014, we completed the sale of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20141229__20141229__us-gaap--SubsidiarySaleOfStockAxis__custom--StockPlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRHJjq2LMdng" title="Sale of stock number of shares issued in transaction">2,000,000</span> shares of our common stock to 18 purchasers (“Stock Placement”) for proceeds totaling $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20141229__20141229__us-gaap--SubsidiarySaleOfStockAxis__custom--StockPlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFSnzqg2TCjj" title="Sale of stock consideration received on transaction">2,000,000</span>, including (a) $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20141229__20141229__us-gaap--SubsidiarySaleOfStockAxis__custom--StockPlacementMember_z2DmyAgD2oBh" title="Proceeds from issuance of common stock">1,625,000</span> of cash and (b) automatic conversion of promissory notes in the principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20141229__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--SubsidiarySaleOfStockAxis__custom--StockPlacementMember_zAoaWFJHPfG1" title="Face amount">375,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NuGene was incorporated in California in December 2006 and formed and funded by our founders, Ali Kharazmi and Mohammed Kharazmi, M.D. The initial focus of NuGene was to develop and market customized skin care products. As part of that focus, NuGene sought to leverage the working relationships developed by our founders with the plastic surgery community. NuGene directed significant time and resources on developing anti-aging and scar treatment/reduction products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2007 Nugene continued to focus on “age-defying” products utilizing peptide complexes (see further description below) and nano-encapsulation for absorption into the skin (see additional description below). We introduced a limited product line under the NuGene name and co-branded the products with an affiliated entity, Genetic Institute of Anti-Aging, Inc. (“GIAA”), which the Kharazmi owned. We utilized the services of a Korean-based contract manufacturer to supply our products. This product line (the “GIAA Line”) was based on peptides and did not utilize stem cells. We had very modest sales in 2007, with our sole customer GIAA, a related party.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2008 we stopped production of the GIAA Line, and sales were limited to selling the remaining inventory through medical offices and GIAA. With the GIAA Line discontinued, we spent the remainder of 2008 considering different formulations and methodologies for improved anti-aging products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2009 and 2010, we had limited activity and minimal sales. Our sales were mainly overseas and limited to the remaining inventory of the GIAA Line. We continued to explore how we might advance our formulations and methodologies. We expended funds on research and development, carried out mainly by scientists engaged by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2011 our founders decided to use adult adipose human stem cells (undifferentiated cells found throughout the body that multiply by cell division to replenish dying cells and regenerate tissues) as the foundation of the formulation for its products. In 2011 the Company developed a proprietary process to extract human adult stem cells from fat cells that the Company then used in its customized NuGene line explicitly made for those client(s). Throughout 2011 we continued to provide autologous, or mature, fat-derived stem cells for use in clinical procedures utilizing this technology. Through this process, the Company refined its ability to culture adult human stem cells to render human-conditioned stem cell media at a proprietary concentration, a primary ingredient in the NuGene line of cosmeceuticals. The Company believes that this proprietary concentration, combined with our unique formulations, will provide NuGene with a significant competitive advantage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2012 we completed our initial line of cosmeceutical products based on these adipose-derived stem cells. We branded this advanced skincare line solely under the NuGene name (the “NuGene Line”). We eliminated the unpleasant odor associated with stem cells by adding a fragrance with a very low incidence of allergic reaction. The packaging of this new product line bears no resemblance to the prior GIAA Line. We also manufactured the NuGene Line ourselves at a small laboratory facility that we leased from an affiliated entity owned by one of our founders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout 2013 we continued to expand the product offerings of the NuGene Line. The Company focused its stem cell work on surgical and orthopedic regeneration. These services were delivered to one client, which was an affiliated entity. Sales of the NuGene Line were limited as we were in an initial rollout and branding phase.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2014, we focused our efforts on transitioning to a cosmeceutical skincare business for mass distribution. With this transition and expanded attention to our consumer products, we sought to develop our marketing plan and distribution channels. By the end of 2014, we had wholesalers distributing products from the NuGene Line to medical offices and medical spas throughout the United States. December 31, 2014, we had about 50 locations selling our products. In addition to the NuGene Line, we generated revenues from an affiliate, Advanced Surgical Partners (“ASP”), which is also owned by our CEO and Chairman of the Board, Messrs. Ali and Mohammed Kharazmi, respectively. Revenues generated from ASP resulted from NuGene providing Plasma Rich Platelet and Stem Cell injections for orthopedic and plastic surgery procedures to ASP. We provided these products and services to ASP as we transitioned into commercializing our cosmeceutical product lines. We expect further to minimize these product sales and services to ASP in early 2015.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our target customers primarily consisted of middle-aged men and women concerned with their aging skin and hair loss. Although our distributors were primarily west of the Mississippi River, our products were sold throughout the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By 2017, our cosmeceutical skincare business had been discontinued as we could not obtain financing for operations on reasonable terms and became inactive. Our corporate charter was revoked in Nevada</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 26, 2020, Emergent, LLC (“Emergent”), a Nevada LLC controlled by Milan I Hoffman, was appointed the custodian of the Company and proceeded to revive the Company’s existence and resolve its outstanding indebtedness. This was completed as to all indebtedness except for one convertible rate promissory note of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200126__20200126__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z6V23okdX8E" title="Debt instrument convertible beneficial conversion feature">120,000</span>. See Litigation. In March 2022, Ms. Hoffman sold her Series A Preferred stock in the Company and certain shares of Series C Preferred Stock to Livento Group, LLC. Also in March 2022, David Stybr, our CEO and the sole owner of Livento Group, LLC, agreed to contribute Livento Group, LLC to the Company in exchange for a transfer to him of the Series A Preferred Stock which gave Mr. Stybr voting control of the Company. The Series C Preferred Stock purchased by Livento Group, LLC was cancelled. As a result of these transactions our current operations are the operations of Livento Group, LLC</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Livento Group operations started in 2017 as the internal team spearheaded the development of financial management software based on artificial intelligence for investment entities. This software currently provides several clients with data processing and analytical services in the investment management sector. Management believes that this segment of our operations will provide meaningful revenue, but we can give no assurance that this will happen. The product is best described as an automated system that can analyze large quantities of data, focusing on selected parameters and predicting short-term future behavior within a specific portfolio of selected assets. The software chooses assets with the highest potential based on a set of specifications and properties, predicting short-term future behavior within a particular portfolio.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2020 the Company acquired land for a residential real estate development project, amounting to <span id="xdx_908_eus-gaap--PaymentsToAcquireResidentialRealEstate_pn6n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zhZ0rkdf4xk1" title="Payments to acquire residential real estate">4</span> million USD, with a completion target of late 2022. The property is being developed into 16 residential condominiums in a suburb of Prague in the Czech Republic, and all of the condominium units have signed purchase agreements totaling <span id="xdx_90A_eus-gaap--PaymentsToAcquireRealEstate_pn6n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zFZNCh4y7aM5" title="Payments to acquire real estate">12</span> million. The development cost was approximately <span id="xdx_90E_eus-gaap--PaymentsToDevelopRealEstateAssets_pn6n6_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zTTD8OUDkarb" title="Payments to develop real estate assets">3</span> million USD. Accordingly, the gross profits from this project (not counting carrying costs) will be about 5 million USD. The Company had one more real estate project in the planning phase but planned to sell it and not develop the property further. The Company invested in a residential project total amount of around <span id="xdx_909_eus-gaap--PaymentsToAcquireAndDevelopRealEstate_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zA2IkjVYaJA3" title="Payments to acquire and develop real estate">825,000</span> USD and is currently looking for a buyer. We have had discussions with three potential buyers and expect to finalize a contract of sale by the end of 2022 but can give no assurances that this will occur or that any sale of this project will prove profitable. We do not have any further plans to engage in additional real estate development projects.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zcgzM1RLHef8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_868_z36HrdUXwL6j">Use of Estimates</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conformity with GAAP requires the use of estimates and judgments that affect the reported amounts in the financial statements and accompanying notes. These estimates form the basis for judgments we make about the carrying values of our assets and liabilities that are not readily apparent from other sources. We base our estimates and judgments on historical information and on various other assumptions that we believe are reasonable under the circumstances. GAAP requires us to make estimates and judgments in several areas, including but not limited to, those related to revenue recognition, collectability of accounts receivable, contingent liabilities, fair value of financial instruments, fair value of acquired intangible assets and goodwill, useful lives of intangible assets and property and equipment, excess and obsolete inventory, deferred tax asset valuation and income taxes. These estimates are based on management’s knowledge about current events and expectations about actions we may undertake in the future. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zah6W8pQjj52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_865_zzFnVxfEzDB8">Risks and Uncertainties</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in an industry that is subject to rapid change. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including the potential of business failure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Reclassifications Reclassifications	<p id="xdx_842_eus-gaap--Reclassifications_zN3w4lCtZdL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_861_zGM2mvyullt3">Reclassifications</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For comparability, certain prior period amounts have been reclassified, where appropriate, to conform to the current year’s financial statement presentation. These reclassifications have no impact on net loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Revenue Recognition Accounting Policy Gross And Net Revenue Disclosure RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure	<p id="xdx_848_eus-gaap--RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure_zeip6e49xkk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_861_z4P84rMol3el">Concentration of Revenues</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Livento Group has been operating in the US and Europe since 2019, and on March 31, 2022, it was acquired by Nugene International, Inc., which subsequently changed its name to Livento Group, Inc. We had revenue of $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331_zQ6uUi6avGIk" title="Revenue">491,468</span> in the first quarter of 2023. These came from sales of Elisee and our management services to real estate projects. Elisee sales accounted for $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--DeferredMovieRevenuesMember_z4lFFBG56Nmc" title="Revenue">277,972</span> and $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--RealEstateProjectsAndManagementMember_zt5Kw2GykaJk" title="Revenue">213,496</span> for real estate projects and management. The Elisee clients have one- or two-years contracts of using our services, but loss of any of our major clients could significantly decrease our revenues and impede our future growth prospects. Real estate proceeded sales are shifter internally into BOXO productions division where diversification in multiple projects is securing long term stability of revenues for the Company. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	491468	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	419353	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	248001268	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	227001268	shares
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5032230	usd
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	120000	usd
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	248001268	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	4500	usd
CY2023Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.03	pure
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	56000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	59000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	61000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	176000	usd

Files In Submission

Name	View Source	Status
0001493152-23-016857-index-headers.html	Edgar Link	pending
0001493152-23-016857-index.html	Edgar Link	pending
0001493152-23-016857.txt	Edgar Link	pending
0001493152-23-016857-xbrl.zip	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nugn-20230331.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
nugn-20230331_def.xml	Edgar Link	unprocessable
nugn-20230331_cal.xml	Edgar Link	unprocessable
nugn-20230331_lab.xml	Edgar Link	unprocessable
nugn-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NUGN
Livento Group Inc Stock $nugn

2023 Q1 Form 10-Q Financial Statement

#000149315223016857 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NUGN Livento Group Inc Stock $nugn

2023 Q1 Form 10-Q Financial Statement

#000149315223016857 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NUGN
Livento Group Inc Stock $nugn